STATEMENT FROM VIREO HEALTH OF NEW YORK CHIEF MEDICAL OFFICER ON FEDERAL ANNOUNCEMENT ON MEDICAL CANNABIS RESEARCH

Statement from

Stephen Dahmer, M.D.

Chief Medical Officer of Vireo Health of New York

Re: Federal announcement reducing barriers for medical cannabis research

August 11, 2016

“We view today’s decision as a small step in the right direction. Under the Compassionate Care Act, we provide seriously-ill patients in New York with third-party tested, extract-only medical cannabis based on recommendations from their physicians. Expanding upon existing research could provide a science-based treatment foundation that will help engage more physicians and in return benefit even more patients, here in the New York State and beyond.

“We strongly support passage of the bi-partisan CARERS Act; legislation that would acknowledge the scientific evidence that cannabis has accepted medical use and give states greater ability to regulate their own medical cannabis programs. Today is encouraging, but additional reforms are overdue at the federal level necessary to improve the accessibility and affordability of medical cannabis for our patients.”

– 30 –

Background: Vireo Health of New York is a physician-led company dedicated to providing best-in-class cannabis-based medications and top quality patient care. The company provides a wide array of pharmaceutical grade cannabis-based products formulated from the highest quality plants and utilizes its separation chemistry capabilities to create products with novel cannabinoid combinations. Vireo Health of New York is a wholly owned subsidiary of Vireo Health, LLC. For more information, visit http:/www.vireohealth.com/ny.